Induction of apoptosis contributes to the cytotoxic action of the intravenously applicable alkylphosphocholine erucylphosphocholine (ErPC). To define molecular requirements for ErPC-induced apoptosis, activation of caspases-8, -9 and -3 and cleavage of the caspase-3 substrates PARP and ICAD were tested in normal Jurkat T cells, Jurkat cells resistant to death receptor (CD95 or TNFarelated apoptosis inducing ligand (TRAIL)-induced apoptosis, Jurkat cells lacking caspase-8 or Fas-associated death domain (FADD) Jurkat cells expressing a dominant-negative caspase-9 or overexpressing Bcl-2 as well as BJAB B-lymphoma cells expressing a dominantnegative FADD (FADD-DN) . ErPC induced a time-and dose-dependent apoptotic cell death in Jurkat and BJAB cells, which was characterized by breakdown of the phosphatidylserine asymmetry, depolarization of the mitochondrial membrane potential, release of cytochrome c, activation of caspases-9, -8 and -3, cleavage of PARP and ICAD, as well as chromatin condensation. ErPCinduced apoptosis was independent from CD95-receptor signaling and FADD since CD95-and TRAIL-resistant, caspase-8-and FADD-negative Jurkat cells, as well as BJAB cells expressing FADD-DN were sensitive to ErPC-induced apoptosis. In contrast, inhibition of caspase-9 and overexpression of Bcl-2 significantly reduced ErPC-induced caspase activation and apoptosis. Thus, ErPC triggers apoptosis via a Bcl-2-dependent mitochondrial but death receptor-independent pathway.
Introduction
In the last decade, cellular membranes have been identified as novel targets for antineoplastic drugs (Noseda et al., 1989) . Alkylphosphocholines (APC) have been proposed as promising membrane targeted antineoplastic drugs, exerting cytotoxic effects in cell culture as well as in animal models (Berger et al., 1993; Clive et al., 1999; Konstantinov and Berger, 1999; Smorenburg et al., 2000; Ruiter et al., 2001) . Similar to alkyllysophospholipids, (ALP), APC primarily interfere with cellular membranes without direct interaction with the DNA (Berggren et al., 1993; Bergmann et al., 1994; Berkovic et al., 1995; Zheng et al., 1990; Lucas et al., 2001) . These lipophilic drugs lack bone marrow toxicity and even exert growth stimulatory effects on hematopoietic progenitor cells inducing leukocytosis and thrombocytosis after systemic application (Vehmeyer et al., 1992; Ergezinger et al., 1999; Berkovic et al., 2001) . Hexadecylphosphocholine (HePC) represents the first APC used in clinical trials (Miltex R ), (Berger et al., 1993; Clive et al., 1999; Konstantinov and Berger, 1999; Smorenburg et al., 2000) . However, because of its gastrointestinal toxicity and its hemolytic side effects, the application of HePC is limited to topical treatment Verweij et al., 1992) .
Erucylphosphocholine (ErPC), an APC-derivative with a 22 carbon atom chain and a cis-13, 14 double bond, is the first derivative suited for intravenous administration. ErPC exerts more potent antineoplastic effects in vitro and in vivo than HePC Konstantinov and Berger, 1999) . Since ErPC lacks the hemolytic effects of HePC and accumulates in diverse tissues after repeated intravenous applications of nontoxic drug doses to rats , it represents the most promising antineoplastic APCderivative. ErPC has been shown to reduce the number of viable tumor cells in vitro. Inhibition of proliferation and induction of apoptosis contribute to its antineoplastic action . ErPC modulates specific intracellular signaling pathways leading to growth arrest in the G2/M phase of the cell cycle and the induction of programmed cell death even in chemoresistant astrocytoma/glioblastoma cell lines (Jendrossek et al., , 2001 ). However, the exact molecular mediators of ErPC-induced apoptosis remain unclear.
Apoptosis is characterized by the activation of a family of cysteine proteases, the caspases. Caspases function during initiation and also as central executioners of apoptosis, and can be activated by two distinct but interrelated signaling pathways (Salvesen and Dixit, 1997; Thornberry and Lazebnik, 1998; Chen and Wang, 2002) . Activation of the death receptor pathways by death receptor ligands leads to rapid activation of the initiator caspase-8 and caspase-8-mediated direct cleavage of downstream effector caspases-3, -6 and -7. CD95-ligand (CD95-L)-induced cell death is paradigmatic for death receptor-induced apoptosis. Binding of CD95-L to its receptor leads to the trimerization of CD95 and subsequent binding of the Fas-associated death domain (FADD)-adapter molecule to an oligomeric death-inducing signaling complex (DISC) (Boldin et al., 1996; Schulze-Osthoff et al., 1998; Daniel et al., 2001 ). FADD in turn recruits procaspase-8 to the DISC mediating the autoproteolytic activation of caspase-8 (Muzio et al., 1996; Salvesen and Dixit, 1999) . Depending on the cell type caspase-8 either directly activates downstream effector caspases such as caspase-3 by proteolytic cleavage or, in cells with low initial caspase-8 activation, via a mitochondrial amplification loop mediated by caspase-8 triggered cleavage of the proapoptotic Bcl-2 protein Bid (Li et al., 1998; Luo et al., 1998) . Cleaved Bid then triggers release of cytochrome c from the mitochondrial intermembrane space with subsequent proteolytic activation of procaspase-9.
The death receptor-independent apoptosis signaling pathways that are triggered by diverse cellular stresses are less defined. It has been shown that mitochondria are central for those death receptor-independent signaling pathways Wesselborg et al., 1999; Newton and Strasser, 2000) . Irrespective of the primary cellular target of the stress signals (DNA, cell volume, cytoskeleton, membrane), the perturbation of mitochondrial functions with breakdown of the mitochondrial membrane potential and release of cytochrome c leads to the cleavage of caspase-9 in the socalled apoptosome, a proapoptotic signaling complex composed of cytochrome c, the adaptor molecule apoptotic protease activating factor-1 (Apaf-1), dATP and procaspase-9 (Li et al., 1997; Zou et al., 1999) . Caspase-9 then cleaves and activates caspase-3 and other downstream effector caspases. Antiapoptotic proteins of the Bcl-2 family, Bcl-2 and Bcl-x L inhibit mitochondrial pathways for the induction of apoptosis Cheng et al., 2001; Li et al., 2001) .
The role of death receptor signaling for APC-induced apoptosis remains controversial. Investigations with brain tumor cells lines led to the assumption that mitochondria may be central for APC-induced apoptosis and that CD95-receptor signaling is not required (Cuvillier et al., 1999; Jendrossek et al., 2001) . However, other reports argue for an involvement of death receptor signaling in cell death induced by APC or the closely related ALP (Cabaner et al., 1999; Gajate et al., 2000; Gajate and Mollinedo, 2001; Matzke et al., 2001) . The aim of the present study was to define the function of death receptor-mediated and mitochondrial signaling pathways for ErPC-induced apoptosis in human leukemic cell lines with functional inactivation of either pathway.
Results

ErPC induces apoptotic cell death, caspase activation and mitochondrial alterations
In a first set of experiments, sensitivity of Jurkat Tlymphoma cells to ErPC-induced apoptosis was analysed. Treatment of Jurkat A3 or Jurkat Vector cells led to a time-and dose-dependent induction of apoptotic cell death. ErPC-concentrations of 25 mm were sufficient to induce significant apoptosis within 12-24 h as determined by flow cytometry (Figure 1a ). In addition, analysis of nuclear morphology revealed chromatin condensation and nuclear segmentation known as typical features of apoptotic cell death (Figure 1b) .
Caspases are key regulators for the induction and execution of apoptosis. Therefore, the activation of caspases upon ErPC-treatment was tested by Western blot analysis. Concentrations of 12.5-50 mm ErPC induced activation of caspases-8, -3 and -9 within 12 h ( Figure 1c, upper panel) . Caspase activation was detectable within 6 h of treatment (Figure 1c , lower panel). The detection of the characteristic processing pattern of PARP and the decrease of full-length ICAD, both substrates of caspase-3 (Sakahira et al., 1998; Stroh and Schulze-Osthoff, 1998) , was also indicative for the activation of caspase-3 ( Figure 1c ). The observation that ErPC induces activation of caspases was further corroborated by FACS analysis using the CaspAce s detection system (Figure 4e ).
Many chemotherapeutic drugs induce apoptosis of cancer cells via mitochondrial pathways Wesselborg et al., 1999; Engels et al., 2000; Wieder et al., 2001) . To elucidate the role of mitochondria in ErPC-induced cell death mitochondrial function of ErPC-treated Jurkat cells was tested in a next set of experiments. ErPC induced a time-and dose-dependent breakdown of the mitochondrial membrane potential as determined by FACS analysis of cells loaded with the potential sensitive dye tetramethylrhodamine-ethylesterperchlorate (TMRE) (Figure 1d ). Furthermore, ErPC triggered a release of cytochrome c from the mitochondrial intermembrane space as indicated by the diffuse staining pattern of the cytosol upon ErPC-treatment. In contrast, the focal staining pattern in untreated cells corresponds to the retention of cytochrome c within the mitochondria (Figure 1e ).
ErPC-induced apoptosis is independent from death receptor signaling
Death receptor signaling involves the adapter molecule FADD that recruits procaspase-8 to the DISC to initiate apoptosis . It has been suggested that at least in some cell types chemotherapyinduced apoptosis might be mediated via drug-induced upregulation of CD95-L and death receptor-mediated activation of caspases Muller et al., 1997; Nomura et al., 2000) . In addition, recent publications suggested an involvement of CD95-receptor signaling in apoptosis induced by the membrane targeted APC and ALP (Cabaner et al., 1999; Gajate et al., 2000; Gajate and Mollinedo, 2001; Matzke et al., 2001) . Since our results revealed activation of caspase-8 upon ErPC-treatment, the role of death receptor pathways, in particular the requirement of FADD and caspase-8 were analysed in a next set of experiments. Our results show that ErPC clearly induced apoptosis in 5, 25 and 50 mm ErPC. Caspase activation was determined by Western blot analysis of cytosolic extracts with specific antibodies against caspase-8 or the cleavage products of caspase-3. In addition, caspase-3 activation was verified by detection of the cleavage of the caspase-3 substrate PARP. (e) Jurkat A3 control cells, CD95-, TRAIL-and CD95/TRAIL-resistant cells were treated for 24 h with medium, 100 ng/ml CH11, 100 ng/ ml TRAIL or 50 mm ErPC. Apoptosis was then determined by flow cytometry using light scatter characteristics. Data show means7s.d. (n ¼ 3)
Erucylphosphocholine-induced apoptosis signaling V Jendrossek et al death receptor stimulation by 100 ng/ml of an agonistic anti-CD95 antibody (clone CH11) in FADD-and caspase-8-deficient Jurkat cells and lack of caspases-8, -3 and PARP cleavage (data not shown). Furthermore, Jurkat cells that were resistant to CD95 and/or TRAIL-induced apoptosis were tested for their sensitivity to ErPC-induced apoptosis. As shown in Figure 2e , ErPC clearly induced apoptosis in both the death receptor-sensitive Jurkat A3 cells and the CD95-, TRAIL-and CD95/TRAIL-resistant Jurkat cells. In contrast, control experiments revealed that only Jurkat A3 control cells were sensitive to CD95-or TRAILinduced apoptosis, while in the death receptor-resistant cell lines CD95-and TRAIL-induced apoptosis was completely abrogated (Figure 2e ).
To further corroborate the finding that ErPC-induced apoptosis occurs independently from FADD-dependent pathways, BJAB lymphoma cells stably expressing a dominant negative FADD (FADD-DN) were also analysed. ErPC triggered apoptotic cell death ( Figure   3a ,b) with no substantial differences between BJAB FADD-DN cells and the respective BJAB vector control cells. Similarly, no differences in the time course and extent of mitochondrial depolarization (Figure 3c ), caspase-activation (not shown) and PARP-cleavage ( Figure 3d ) were observed. Expression of the FADD-DN was analysed by Western blot (Figure 3e ). As a control for functional activity of the FADD-DN construct, BJAB Vector and BJAB cells expressing the FADD-DN were stimulated with a recombinant TRAIL. While BJAB Vector cells were highly sensitive to death receptor-induced apoptosis upon death receptor stimulation apoptosis was completely abrogated in BJAB FADD-DN cells (Figure 3b ).
Mitochondria and caspase-9 are central for ErPC-induced apoptosis Some chemotherapeutic drugs have been shown to induce cell death via mitochondrial pathways (Fulda Wesselborg et al., 1999; Wieder et al., 2001 ). Since our data revealed that ErPC induced characteristic mitochondrial alterations in Jurkat cells, we speculated that ErPC may act via mitochondrial, death receptorindependent pathways. In this regard, it was shown that overexpression of Bcl-2 strongly interfered with mitochondrial damage and cell death (Rudner et al., 2001b) . To gain further insight into the importance of mitochondria for ErPC-induced cell death, Jurkat cells overexpressing Bcl-2 were treated with ErPC and tested for apoptotic changes. While ErPC induced a timeand concentration-dependent apoptosis in the vector control cells, overexpression of Bcl-2 almost completely abrogated ErPC-induced apoptotic cell death as determined by nuclear morphology, membrane alterations (not shown) and light scatter characteristics (Figure 4a) .
Furthermore, while vector control cells were rather sensitive to ErPC-induced alterations of the mitochondria, overexpression of Bcl-2 significantly reduced depolarization of the mitochondrial membrane potential upon ErPC-treatment (Figure 4c ). In addition, ErPC failed to induce release of cytochrome c from the mitochondrial intermembrane space of Bcl-2 overexpressing Jurkat cells (Figure 4d ). In accordance with these findings, Bcl-2 also interfered with ErPC-induced activation of caspases (Figure 4e ). While in Jurkat Vector cells, 12.5 mm ErPC was sufficient to induce activation of caspases-8, -9, and -3 as well as processing of PARP and ICAD, in Bcl-2-overexpressing Jurkat cells high concentrations (50 mm) of ErPC were required to initiate caspase cleavage. These data imply that caspase-activation occurs downstream of the mitochondria.
Expression of Bcl-2 was controlled by Western blot analysis (Figure 4b ). Functional activity of Bcl-2 was confirmed by its inhibitory effect on radiation-induced apoptosis (not shown).
Up to this point our data indicated that ErPC triggers mitochondrial alterations, caspase activation and apoptosis independently of FADD and caspase-8. Caspase-9 has been shown to function as the initiator caspase in mitochondrial apoptosis pathways (Li et al., 1997; Stepczynska et al., 2001; Chen and Wang, 2002) . Therefore, the role of caspase-9 in ErPC-induced apoptosis was analysed in Jurkat cells expressing a dominant-negative caspase-9 (caspase-9 DN). Our results show that the expression of the caspase-9 DN reduced ErPC-induced apoptosis, activation of caspase-3 and PARP processing (Figure 5a,b) . The differences in apoptosis sensitivity have also been determined at 24 h and remained clearly visible (63.877.7% apoptotic vector control cells compared to 26.972.5% apoptotic caspase-9 DN cells 24 h after treatment with 25 mm ErPC). Furthermore, caspase-9 was also activated upon ErPC-treatment of caspase-8-or FADD-negative Jurkat cells, respectively, while being absent in caspase-8-or FADD-negative Jurkat cells treated with the activating anti-CD95 antibody CH11 (Figure 5c ). Taken together our data prove a central role of mitochondria and caspase-9 for ErPC-induced cell death.
Discussion
In the present study, we characterized intracellular mediators of ErPC-induced cytotoxicity in human leukemic T-and B-cell lines. In particular, our data provide evidence that ErPC induces apoptosis in Jurkat T-cells and BJAB B-lymphoma cells independently from death receptor signaling and FADD. In contrast, overexpression of Bcl-2 and inhibition of caspase-9 interfered with ErPC-induced cell death pointing to a central role of the mitochondria for the signaling cascade.
The observation that ErPC-induced cytotoxicity in human leukemic cell lines is mediated via apoptosis is consistent with earlier reports that APC induce apoptotic cell death in cell lines from solid tumors or leukemic cell lines (Engelmann et al., 1996; Jendrossek et al., 1999 Jendrossek et al., , 2001 Konstantinov et al., 1998; Wieder et al., 1998) . Here, we demonstrate that ErPC treatment of Jurkat T cells and BJAB B cells results in the activation of caspase-8, -3 and -9, and the cleavage of cellular caspase-3-substrates such as PARP and ICAD, and thus has all hallmarks of classical apoptosis. This is of special interest since these drugs had been suggested to induce apoptosis via distinct pathways initiated at the cytoplasma membrane independently from a direct interaction with the DNA.
Earlier reports pointed to an involvement of CD95 and FADD in apoptosis induced by APC or the closely related ALP (Cabaner et al., 1999; Gajate et al., 2000; Gajate and Mollinedo, 2001; Matzke et al., 2001) , while others suggested CD95-independent signaling pathways (Cuvillier et al., 1999) . Therefore, the observed activation of caspase-8 led to the assumption that death receptor pathways might be required for ErPC-induced cell death. During death receptor signaling, procaspase-8 is recruited to the DISC via the adaptor molecule FADD, activated by autoproteolytic cleavage and then required for the activation of downstream effector caspases such as caspase-3 (Varfolomeev et al., 1998) . However, our results clearly show that caspase activation and apoptosis were also triggered in FADD-and caspase-8-negative cells, as well as in cells overexpressing a FADD-DN. In addition, cells that were selected for resistance to death receptor-induced apoptosis turned out to be highly sensitive to ErPC-induced cell death. Thus, ErPC-induced caspase activation and apoptosis occurred independently from FADD and death receptor signaling. The data presented here are consistent with our own observations on independence of ErPC-induced apoptosis from CD95 signaling in human astrocytoma/glioblastoma cell lines and also exclude a role of a CD95-L-independent but FADDdependent mechanism of caspase activation as described previously (Micheau et al., 1999) . The discrepancy between our results and the observations on the involvement of the CD95/CD95-L system in ether lipid-induced cell death might be because of the use of the APC ErPC instead of the alkyllysophospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (Et-18-OCH 3 ), as well as the use of distinct cell lines. .
Data show one representative of three independent experiments
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Together with other reports showing that apoptosis induced by chemotherapeutic agents does not require death receptor signaling Wesselborg et al., 1999; Engels et al., 2000; Wieder et al., 2001) , our data further corroborate the finding that drug induced upregulation of CD95-L-and death receptormediated activation of caspases is not a common signaling mechanism for chemotherapy-induced apoptosis.
On the other hand, mitochondria have been demonstrated to function as key players during drug-and radiation-induced apoptosis. Antiapoptotic proteins of the Bcl-2 family, Bcl-2 and Bcl-x L , antagonize those mitochondrial pathways for the activation of caspases and the induction of apoptosis by inactivation of proapoptotic Bcl-2 proteins and inhibition of cytochrome c release and/or caspase-9 activation (Cheng et al., 2001; Belka and Budach, 2002; Rudner et al., 2002) . In this regard, overexpression of Bcl-2 has been shown to confer drug resistance in leukemic tumor cells (Miyashita and Reed, 1993) . Since our data revealed an activation of mitochondria upon treatment with ErPC, we analysed whether overexpression of Bcl-2 would also interfere with ErPC-induced apoptosis. In our hands, functional inactivation of the mitochondria by overexpression of Bcl-2 inhibited ErPC-induced caspaseactivation and cell death. This finding is consistent with the observation that Bcl-2 or Bcl-x L may interfere with apoptosis induction upon treatment with the ALP Et18-OCH 3 (Mollinedo et al., 1997; Cuvillier et al., 1999) and demonstrates that mitochondria are central for ErPCinduced apoptosis signaling pathways.
The alteration of mitochondrial functions with breakdown of the mitochondrial membrane potential and release of cytochrome c has been shown to result in the cleavage of caspase-9, which then activates caspase-3 and other downstream effector caspases (Li et al., 1997; Hakem et al., 1998; Stepczynska et al., 2001; Chen and Wang, 2002) . In this context, caspase-9 represents the most apical caspase, while cleavage of caspase-8 occurs only downstream of the caspase-9 and functions as an effector caspase Engels et al., 2000; Stepczynska et al., 2001) . Therefore, we analysed whether caspase-9 was required for ErPC-induced cell death. Our data show for the first time that expression of a caspase-9 DN strongly interfered with ErPC-induced caspase-activation and apoptosis. Thus, caspase-9 is essential for ErPC-triggered apoptosis and may represent the initiator caspase that is activated downstream of the mitochondria. This finding is further corroborated by the observation that caspase-8 was activated in parallel to caspases-9 and -3 in a Bcl-2 controlled manner. This is reminiscent of apoptosis signaling initiated by radiation and some chemotherapeutic drugs, and implies that also during ErPC-triggered apoptosis caspase-8 functions as an effector caspase that is activated downstream of caspases-9 and -3. This caspase-3-mediated activation of caspase-8 has been shown to initiate a mitochondrial amplification loop via cleavage of Bid (Li et al., 1998; Belka et al., 2000) . Since deficiency of caspase-8 caused a delay but not an inhibition of ErPC-induced cell death, a similar mechanism might be operative during ErPC-induced apoptosis which is omitted in caspase-8-deficient cells.
The signaling pathways upstream of the mitochondria are less defined. It has been suggested that formation of ceramide, a cellular second messenger that accumulates in cells upon diverse cellular stresses, may contribute to apoptotic signaling of lipophilic drugs, such as Et18-OCH 3 and APC (Ruiter et al., 1999 (Ruiter et al., , 2001 . In this regard, it has been shown that ceramide induces apoptosis via a bax-dependent mitochondrial pathway that is inhibited by overexpression of Bcl-2 (Raisova et al., 2001 (Raisova et al., , 2002 von Haefen et al., 2002) . Furthermore, ceramide has been implicated into changements of membrane lipid composition (Huang et al., 1999) leading to the clustering of receptor molecules in specialized cholesterol and sphingolipid-rich cell membrane domains, termed rafts (Grassme et al., 2001) . The concentration of signaling molecules, that is death receptors, in these signaling platforms was sufficient to trigger death receptor signaling even in the absence of the respective ligands mediating self-association of the death domains (Boldin et al., 1995) . In this context, it was shown that Et-18-OCH 3 triggers apoptosis through intracellular CD95-L-independent capping of CD95 within membrane rafts (Gajate et al., 2000) . In our hands, ErPC-induced apoptosis did not require FADD and caspase-8. Since signaling events initiated by intracellular clustering of CD95 should be dependent on both effector molecules, our results argue against a similar mechanism for ErPC-induced cell death in Jurkat cells. However, we cannot exclude that formation of rafts may contribute to the proapoptotic action of ErPC since other molecules activated within those lipid rafts such as protein tyrosine kinases may be critical for downstream apoptotic signaling (Cinek et al., 1995) .
Ceramide can function as a putative upstream activator of Jun-N-terminal kinase (JNK) (Verheij et al., 1996) . It has been demonstrated that ALP and APC induce activation of JNK and that antisense oligonucleotides against c-jun or overexpression of a dominant-negative c-Jun blocked Et-18-OCH 3 -induced apoptosis (Mollinedo et al., 1994; Gajate et al., 1998; Ruiter et al., 1999) . Recent data revealed a requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway (Tournier et al., 2000) . In addition, irradiation of cells induced a translocation of JNK to the mitochondria and an association of the kinase with Bcl-x L (Kharbanda et al., 2000) . Thus, the generation of ceramide with subsequent activation of JNK in response to the treatment with APC may constitute the missing link between drug effects on cellular membranes and the mitochondria.
Despite the similarities in the signaling pathways downstream of the mitochondria, ErPC and other synthetic phospholipid analogues displayed no crossresistance towards DNA-damaging drugs or irradiation and even showed additive or synergistic effects in combination experiments in vitro (Noseda et al., 1988; Stekar et al., 1995; Berkovic et al., 1997; Jendrossek et al., 2001; Ruiter et al., 2001; Georgieva et al., 2002) . Therefore, these drugs may be particularly useful for the treatment of tumor cells resistant to DNA-damaging drugs or irradiation, as well as for combined treatment protocols. Since ErPC can bypass the requirement for death receptor signaling, it may also be useful for a combination with death receptor-dependent anticancer agents such as TRAIL (Belka et al., 2001) .
In conclusion, our results clearly demonstrate that ErPC induces apoptosis in human leukemic cell lines independently from death receptor signaling and FADD via a Bcl-2-and caspase-9-dependent mitochondrial signaling pathway. The molecular details of the interaction of ErPC with the mitochondria remain to be elucidated.
Materials and methods
Chemicals and drugs
ErPC were synthesised by H Eibl, Max Planck Institute of Biophysical Chemistry, Go¨ttingen, Germany. ErPC was dissolved in 200 ml ethanol and diluted with RPMI1640 medium supplemented with 10% fetal calf serum to a concentration of 10 mm (stock solution). The final ethanol concentrations in the tissue culture experiments were below 0.05%.
TMRE was from Molecular Probes (Mobitec, Goettingen, Germany). Hoechst 33342 was purchased from Calbiochem (Bad Soden, Germany) and dissolved in distilled water as a 1.5 mm stock solution. The anti-CD95 (FAS) stimulating antibody (clone CH11) was from Upstate (Biomol, Hamburg, Germany), mouse anti-cytochrome c and mouse anti-caspase-9 were from Pharmingen (Becton and Dickinson, Heidelberg, Germany), rabbit anti-cleaved caspase-3, rabbit anti-cleaved caspase-9, rabbit anti-cleaved PARP, rabbit anti-PARP and rabbit anti-ICAD (DFF45/35) were from Cell Signaling (New England Biolabs, Schwalbach/T, Germany) and the horseradish peroxidase-conjugated sheep anti-mouse IgG was from Amersham-Pharmacia Biotech (Freiburg, Germany). Caspase-8 was detected with a mouse monoclonal antibody directed against the p18 subunit as described previously used as a 1 : 10 dilution of the hybridoma supernatant. Recombinant human TRAIL was from R&D (Minneapolis, MN, USA). All other chemicals were purchased from SigmaAldrich (Deisenhofen, Germany) if not otherwise indicated.
Cell culture
Jurkat A3 T-lymphoma cells were from ATCC (Bethesda, MD, USA). The expression vector for the T7 tagged caspase-9 DN mutant was a kind gift from E Alnemri (Philadelphia, PA, USA). Caspase-9 DN-expressing Jurkat cells were prepared as follows: electroporation was performed using a Gene pulser II electroporation device (Biorad, Munich, Germany). In brief, 10 8 Jurkat cells were washed twice with TBS buffer pH 7.4 prior to transfection. A measure of 25 mg DNA was electroporated with 125 mF and 500 V. Cells were selected with 800 mg/ml G418 (Clontech, Heidelberg, Germany).
The BJAB Vector, BJAB FADD-DN, caspase-8 and FADD-negative Jurkat cells, as well as the Bcl-2-overexpressing Jurkat cells and the respective vector control cells were used as already described Rudner et al., 2001a,b) . Cells were grown in RPMI 1640 medium (Gibco Life Technologies, Eggenstein, Germany) and maintained in a humidified incubator at 371C and 5% CO 2 .
For selection of death receptor-resistant cells, Jurkat A3 cells were cultured for 4 months in the presence of increasing concentrations of an activating anti-CD95 antibody (clone CH11), TRAIL or a combination of both. Final concentrations applied were 200 ng/ml CH11 and 10 ng/ml TRAIL.
Determination of apoptosis
Cell death was quantified by FACS using light scatter characteristics employing a FACS Calibur flow cytometer (Becton Dickinson, Heidelberg, Germany). For quantification of the breakdown of the phosphatidylserine asymmetry during induction of apoptosis, cells were submitted to FACS analysis upon FITC-annexin labeling. In brief, cells were washed twice in annexin washing buffer (10 mm HEPES pH 7.4, 140 mm NaCl, 5 mm CaCl 2 ), incubated for 15 min in the dark in annexin washing buffer supplemented with FITC-annexin (1 : 100; Roche Biochemicals, Mannheim, Germany) and subjected to FACS analysis.
When indicated, apoptosis was also analysed after staining of the cells with Hoechst 33342 and subsequent fluorescence microscopy. In brief, cells were incubated with Hoechst 33342 at a final concentration of 1.5 mm for 15 min. Cell morphology was then determined by fluorescence microscopy (Zeiss Axiovert 200, Carl Zeiss, Jena, Germany) using an excitation wavelength filter of 380 nm. Cells were analysed with Â 40 magnification and documented using an CCD camera device (Zeiss Axiocam MRm).
Determination of caspase activation
Activation of caspases was quantified using the CaspAce s detection system (Promega, Mannhein, Germany) that allows in vivo staining of active caspases. The CaspAce s staining was performed according to the manufacturer's guidelines.
Furthermore, caspase activation was determined by Western blot analysis of cytosolic extracts upon ErPC-treatment. To this end, cells (1 Â 10 6 ) were lysed for 20 min on ice in 25 mm HEPES, 0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 10 mm EDTA, 10 mm NaF and 125 mm NaCl. After removing insoluble material by centrifugation for 15 min at 13 000 rpm, 20 mg lysate was separated by SDS-PAGE were blotted onto PVDF-membranes (Pharmacia, Freiburg, Germany). Equal protein loading was confirmed by Ponceau S staining (Sigma). Blots were blocked for 1 h in PBS buffer containing 0.05% Tween-20 and 5% nonfat dried milk overnight. The membrane was incubated overnight at 41C with the respective primary antibodies. After repeated washings with PBS/Tween-20 (0.05%), the membrane was incubated with the secondary antibody (anti-IgG-AP 1 : 10 000, Santa-Cruz-Biotech, Heidelberg, Germany) in PBS/Tween for 1 h at room temperature and again washed several times with PBS/ Tween. The detection of antibody binding was performed by enhanced chemoluminescence staining (ECL Western blotting analysis system, Amersham-Pharmacia Biotech, Freiburg, Germany).
Determination of mitochondrial transmembrane potential and cytochrome c release
The mitochondrial transmembrane potential (Dc m ) was analysed using the Dc m -specific stain TMRE (Molecular Probes, Mobitech, Go¨ttingen Germany). Briefly, 10 5 cells were loaded for 10 min at 371C with 25 nm TMRE and subsequently analysed by flow cytometry. Preincubation with 1 mm of the proton ionophor carbonylcyanide-m-chlorophenylhydrazone (CCCP) was used as a positive control for complete depolarization of the mitochondrial membrane potential.
The release of cytochrome c from the mitochondria was determined by fluorescence microcopy using an Zeiss Axiovert 200 microscope. In brief, cells were immobilized on cover slips with 0.1% poly-l-lysine, fixed with 2.5% formaldehyde in PBS and permeabilized with 0.1% Triton X-100 in PBS. After blocking with 10% fetal calf serum, cells were stained with the anticytochrome c primary antibody (Becton and Dickinson/ PharMingen, Heidelberg, Germany) for 1 h at room temperature. Cells were washed several times and incubated with the secondary antibody (Alexa Fluort-conjugated anti-mouse antibody, Molecular Probes, Mobitech, Go¨ttingen, Germany) for 45 min. Finally, the cover slips were mounted with Mowiol (Sigma). Cells were analysed with Â 100 magnification and documented using an CCD camera device (Zeiss Axiocam MRm).
Statistical evaluation
Experiments were at least performed in triplicates. Results are means7standard deviation (s.d.) except indicated otherwise.
Abbreviation:
ALP, alkyllysophospholipid; APC, alkylphosphocholine; CCCP, carbonylcyanide-m-chlorophenylhydrazone; DISC, death-inducing signaling complex; ErPC, erucylphosphocholine; FADD, fas-associated death domain; HePC, hexadecylphosphocholine; Et-18-OCH 3 , 1-O-octadecyl-2-O-methyl-racglycero-3-phosphocholine; CD95-L:, CD95 ligand; TMRE:, tetramethylrhodamine-ethylester-perchlorate; TRAIL:, TNFarelated apoptosis inducing ligand.
